Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$75.34
+0.7%		$66.92
$29.95
▼
$118.84
$3.37B3.24938,856 shs267,958 shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$80.80
+3.2%		$73.72
$40.00
▼
$99.50
$3.10B1582,048 shs104,467 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$42.38
-2.4%		$38.41
$8.03
▼
$47.84
$2.65B2.21860,718 shs215,854 shs
NantKwest, Inc. stock logo
NK
NantKwest
$6.98
+1.7%		$28.01
$2.52
▼
$45.42
$763.23M2.611.57 million shs16.54 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+7.71%+6.50%+3.94%+20.75%+128.03%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
+1.08%+2.58%+2.21%+14.23%+34.90%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-4.34%+8.96%+5.06%+9.90%+449.37%
NantKwest, Inc. stock logo
NK
NantKwest
0.00%0.00%0.00%0.00%+186.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$75.34
+0.7%		$66.92
$29.95
▼
$118.84
$3.37B3.24938,856 shs267,958 shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$80.80
+3.2%		$73.72
$40.00
▼
$99.50
$3.10B1582,048 shs104,467 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$42.38
-2.4%		$38.41
$8.03
▼
$47.84
$2.65B2.21860,718 shs215,854 shs
NantKwest, Inc. stock logo
NK
NantKwest
$6.98
+1.7%		$28.01
$2.52
▼
$45.42
$763.23M2.611.57 million shs16.54 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+7.71%+6.50%+3.94%+20.75%+128.03%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
+1.08%+2.58%+2.21%+14.23%+34.90%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-4.34%+8.96%+5.06%+9.90%+449.37%
NantKwest, Inc. stock logo
NK
NantKwest
0.00%0.00%0.00%0.00%+186.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRAIL, Inc. stock logo
GRAL
GRAIL
2.30
Hold$67.78-10.04% Downside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.75
Moderate Buy$106.0031.19% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$48.1413.61% Upside
NantKwest, Inc. stock logo
NK
NantKwest
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NK, GRAL, IRON, and KOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$118.00 ➝ $120.00
8/3/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$56.00 ➝ $66.00
7/17/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/15/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$58.00 ➝ $65.00
7/10/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/15/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$80.00 ➝ $85.00
6/10/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$88.00
6/5/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$60.00
6/5/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$60.00
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M22.87N/AN/A$66.13 per share1.14
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$19.52 per shareN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.97 per shareN/A
NantKwest, Inc. stock logo
NK
NantKwest
$40K19,080.70N/AN/A$1.23 per share5.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%N/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.58N/AN/AN/AN/A-37.17%-33.65%N/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)
NantKwest, Inc. stock logo
NK
NantKwest
-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/A

Latest NK, GRAL, IRON, and KOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.9565N/AN/AN/AN/AN/A
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/30/2026Q2 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.71-$1.54+$0.17-$1.54$1.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
NantKwest, Inc. stock logo
NK
NantKwest
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.09
24.14
24.14
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
3.54
3.54
NantKwest, Inc. stock logo
NK
NantKwest
N/A
4.74
4.74

Institutional Ownership

CompanyInstitutional Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
NantKwest, Inc. stock logo
NK
NantKwest
9.38%

Insider Ownership

CompanyInsider Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
44.40%
NantKwest, Inc. stock logo
NK
NantKwest
71.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36044.67 million43.85 millionOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3038.39 million36.95 millionNot Optionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9062.58 million34.79 millionOptionable
NantKwest, Inc. stock logo
NK
NantKwest
160109.35 millionN/ANot Optionable

Recent News About These Companies

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294926/0/en/gt-biopharma-announces-first-patient-dosed-in-phase-1-trial-of-gtb-5550-a-b7-h3-targeted-natural-killer-nk-cell-engager-for-solid-tumors.html
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
September 4, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34577337/nk-cell-therapy-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies/
Piper Sandler Upgrades ImmunityBio (IBRX)
May 21, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/piper-sandler-upgrades-immunitybio-ibrx/ar-AA1Fb7J5
HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation
March 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/hc-wainwright-co-initiates-coverage-of-immunitybio-ibrx-with-buy-recommendation/ar-AA1AoIt5
Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments
February 4, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4754373-aardvark-therapeutics-starts-100-million-ipo-effort-for-hunger-treatments
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation
January 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/btig-initiates-coverage-of-immunitybio-ibrx-with-buy-recommendation/ar-BB1rgp8f
Northern Knights Cricket Team
August 3, 2024  |  espncricinfo.comE
Natural Killer Cells Therapeutics Market Projections: Anticipated Trends and Developments
May 27, 2024  |  taiwannews.com.twT
From Culture to Clinic: Scale Up NK Cell Expansion
May 1, 2024  |  the-scientist.comT
P!nk puts on showstopping performance for first TSV show
March 25, 2024  |  townsvillebulletin.com.auT
Space NK Promo Code - Up to £330 off
March 16, 2024  |  glamourmagazine.co.ukG
Use of Allogeneic NK Cells for Cancer Immunotherapy
March 2, 2024  |  medscape.comM
Space NK Promo Code - Up to £120 off
February 18, 2024  |  glamourmagazine.co.ukG
Space Nk Promo Codes
February 4, 2024  |  time.comT
NK Industries Ltd.
December 12, 2023  |  ndtv.comN
NK Gupta
November 28, 2023  |  hindustantimes.comH
P!NK's concert in Phoenix: Acrobatic spectacle, raw emotion and Brandi Carlile's last stop
October 23, 2023  |  azcentral.comA
P!NK's 2023 tour setlist: 'Who Knew,' 'So What' and every song she sang in Phoenix
October 18, 2023  |  azcentral.comA
Space NK beauty advent calendar 2023 early access waitlist now open
September 15, 2023  |  thesun.co.ukhttps://www.thesun.co.uk/shopping/15697374/space-nk-advent-calendar/
Frankie Bridge shares her new Space NK beauty buys including concealer people 'love'
August 13, 2023  |  mirror.co.ukM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
AST SpaceMobile logo above a satellite in orbit over Earth, highlighting space-based wireless expansion.
AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
By Jessica Mitacek | July 17, 2026
First Internet Bancorp logo illuminated on a glass panel beside a bank card and smartphone with financial charts.
System Upgrade: First Internet Bancorp Options Surge
By Jeffrey Neal Johnson | August 4, 2026
Voltmax electrical equipment and cable spools at an industrial construction site with a steel-framed building under construction.
3 Non-Tech Stocks Still Winning Big on AI
By Nathan Reiff | July 13, 2026
GRAIL stock logo

GRAIL NASDAQ:GRAL

$75.34 +0.50 (+0.67%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$80.80 +2.52 (+3.21%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$42.38 -1.02 (-2.36%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

NantKwest stock logo

NantKwest NASDAQ:NK

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas